

ASX Release 30 July 2026

Quarterly Activities Report and Appendix 4C for the Quarter Ended 30 June 2026

Epsilon Healthcare Delivers 72% YOY Increase in June Quarter Receipts

Highlights:

- **Record quarterly receipts: \$3.66m for the June 2026 quarter, highest in Company's history, a 17% increase on the previous quarter high**
- **Group revenue \$4.7m for the quarter, YTD averaging \$1.33 million per month tracking at \$16m annualised**
- **Epsilon Pharma, the Company's onshore CDMO delivered YOY growth of 122% for the June quarter from expanding manufacturing activities**
- **Since its establishment 12 months ago, Epsilon Pharmacy now delivering \$2.3m in annualised revenue**
- **New business contracts, expanded import quotas and diversified manufacturing certifications providing new & expanded opportunities both within Australia and into international markets**

Epsilon Healthcare Limited (ASX: EPN)

Epsilon Healthcare Limited ("Epsilon" or "the Company"), is pleased to announce its quarterly activities and Appendix 4C cash flow report for the quarter ended 30 June 2026.

The Company delivered record customer receipts for the June quarter, representing the strongest quarterly performance in its history and a significant milestone in the execution of its long-term growth strategy. The result reflects continued operational execution, increasing customer engagement and the successful scaling of the Company's healthcare platform and strategic initiatives.

The quarter's performance reinforces the strength of the Company's underlying business model and its ability to convert strategic investment into sustained commercial outcomes. Continued growth across the Company's core healthcare offerings supports confidence in the scalability of its operations, the resilience of customer demand and the opportunity to further expand revenue as the business continues to mature.

Importantly, the Company has established a strong platform from which to pursue its next phase of growth. Ongoing investment in capability, capacity and innovation is enhancing operational efficiency, broadening the Company's addressable market, both domestically and internationally, and strengthening its competitive position across key healthcare segments.

The Company remains focused on disciplined execution of its strategic priorities as it progresses towards its ambition of becoming a high performing diversified healthcare company. By expanding its portfolio of healthcare services & assets, leveraging scalable operating infrastructure and pursuing targeted growth opportunities in Australia and selected international markets, the Company believes it is well positioned to deliver sustainable long-term growth and create enduring value for shareholders.

Financial Performance

Epsilon delivered a strong financial performance for the quarter ended 30 June 2026, generating customer receipts of \$3.66 million, representing a 72% increase on the corresponding quarter in 2025. The result reflects continued operational momentum and demonstrates the Company's ability to execute its strategic growth initiatives while expanding its commercial footprint across multiple healthcare segments.

Growth was driven by increasing demand across each of Epsilon's operating divisions, including its onshore Contract Development and Manufacturing operations in Southport, Epsilon Clinics and the recently established Epsilon Pharmacy business. The broad-based contribution across the Company's integrated healthcare platform highlights the benefits of its diversified business model and the increasing depth of customer engagement across its service offering.

The quarter's performance reinforces the successful execution of Epsilon's integrated healthcare strategy and the strength of its expanding market presence.

Building on this strong operational momentum, the Company generated consolidated revenue of \$4.7 million for the three months ended 30 June 2026, representing a 43% increase on the preceding quarter (\$3.3 million for the three months to 31 March 2026). The continued growth reflects increasing commercial traction across the business and demonstrates the scalability of Epsilon's integrated healthcare platform as demand continues to strengthen across both its clinical, supply and manufacturing operations.

The Company has now achieved an annualised revenue run rate of approximately \$16 million, based on June quarter performance, equivalent to approximately \$1.33 million per month. This reflects the continued expansion of Epsilon's diversified revenue base and the successful execution of its strategic growth initiatives.

With positive momentum across each of its operating divisions, Epsilon remains well positioned to further scale its operations, deepen customer engagement and capitalise on attractive growth opportunities across the healthcare sector. The Company continues to focus on disciplined execution, operational excellence and strategic investment to support sustainable long-term growth.

Managing Director Commentary

Epsilon Healthcare Managing Director and CEO, Peter Giannopoulos, said:

"The June quarter represents a defining milestone in Epsilon Healthcare's growth journey, with the Company delivering record customer receipts of \$3.66 million, an increase of 72% on the corresponding period in 2025. This performance reflects the successful execution of our strategic priorities, the continued diversification of our healthcare platform and the increasing commercial momentum being generated across the business.

The achievement demonstrates the strength of our integrated operating model and our ability to translate strategic investment into sustainable commercial outcomes. With customer receipts now exceeding \$1.33 million per month and a disciplined operating cost base, Epsilon is progressively enhancing operating leverage as the business continues to scale. Encouragingly, we are also seeing a growing pipeline of opportunities across both Australian and international markets, reinforcing the scalability of our platform and the increasing demand for our suite of integrated healthcare and manufacturing capabilities.

As we progress through 2026, our focus remains firmly on disciplined execution, expanding our market presence and strengthening the foundations for long-term growth. We will continue investing in capability, innovation and operational excellence while pursuing opportunities that complement our integrated strategy and deliver sustainable value creation.

The momentum established during the June quarter provides a strong foundation for the Company's next phase of growth. Supported by a scalable operating platform, diversified revenue streams and an expanding opportunity pipeline, Epsilon is well positioned to continue executing its strategy and delivering long-term value for shareholders”.

Operational and Commercial Update

Epsilon Pharma (CDMO)

Epsilon's onshore contract development and manufacturing business delivered a strong performance during the quarter, underpinned by sustained GMP manufacturing activity, the continued expansion of its product and service offering, and a growing pipeline of high-quality contract opportunities. Increased manufacturing volumes reflected broadening demand across a diversified customer base, reinforcing the commercial momentum being generated within the business.

A key strategic milestone during the quarter was the successful renewal of Epsilon Pharma's Medicinal Cannabis Permit for the manufacture of finished medicinal cannabis products. Importantly, the renewed permit authorises a substantially increased manufacturing capacity, providing the Company with the flexibility to support a significantly higher level of commercial production as customer demand continues to expand. This enhanced manufacturing capability represents an important enabler of Epsilon's next phase of growth, increasing production capacity while strengthening the Company's ability to service both Australian and international customers. The renewal also reflects the maturity of Epsilon Pharma's quality management systems, regulatory capabilities and manufacturing expertise, reinforcing its position as a trusted GMP manufacturing partner.

The performance further validates Epsilon Pharma's strategic growth trajectory and highlights the scalability of its manufacturing platform. As the Company continues to expand its domestic customer base while developing a growing portfolio of international partnerships, Epsilon Pharma is well positioned to capitalise on increasing demand for high-quality contract development and manufacturing services. The combination of Australian and European GMP licensures provides a differentiated competitive advantage, enabling the Company to manufacture to internationally recognised quality standards and support customers seeking access to multiple regulated markets.

Consistent with its long-term growth strategy, Epsilon continues to invest in expanding manufacturing capacity, strengthening technical and operational capability, and broadening its portfolio of GMP-manufactured products and services. These investments are expected to enhance operational flexibility, deepen customer relationships and support continued revenue diversification as the business scales.

The Board remains committed to building a diversified, innovation-led healthcare company through disciplined investment in capability, infrastructure and service expansion. By continuing to develop new products and manufacturing solutions that respond to evolving client, patient and consumer needs, Epsilon is strengthening its competitive position across the healthcare value chain while creating additional avenues for sustainable growth.

Epsilon Clinics

Epsilon Clinics delivered another strong quarter, supported by sustained patient activity, a high proportion of repeat patient consultations and an expanding active patient base. These operating metrics continue to underpin a growing base of recurring revenue and demonstrate the strength of the division's integrated telehealth model, which delivers high-quality clinical care while expanding patient access and reinforcing its position as an important contributor to the Group's diversified healthcare platform.

The continued growth of the Clinics division reflects increasing demand for accessible, technology-enabled healthcare services and highlights the scalability of its operating model. High levels of repeat patient engagement demonstrate the strength of clinical outcomes and continuity of care, while the expanding active patient list provides a solid foundation for future organic growth. As patient engagement continues to deepen, Epsilon Clinics is well positioned to broaden its patient base, expand its clinical service offering and respond to evolving healthcare needs across Australia, while selectively pursuing opportunities in international markets over time.

As a core component of Epsilon's integrated healthcare ecosystem, Epsilon Clinics complements the Group's contract development and manufacturing, pharmacy and distribution operations, creating an integrated patient and customer pathway across the healthcare value chain. This model supports continuity of care, strengthens patient engagement and generates strategic synergies across the Group's diversified operations, while providing opportunities to enhance lifetime patient value and expand complementary healthcare services.

The Company continues to invest in digital capability, clinical excellence and service innovation to support the ongoing evolution of the Clinics division. These investments are expected to enhance operational efficiency, broaden the range of clinical services available through the platform and further improve the patient experience, strengthening the division's ability to meet evolving healthcare needs.

With a scalable operating model, recurring patient revenue, strong patient retention and a growing active patient base, Epsilon Clinics is well positioned to support the Company's long-term growth strategy. As the business continues to evolve, the division is expected to play an increasingly important role in diversifying revenue, strengthening Epsilon's integrated healthcare platform and delivering sustainable long-term value for patients, healthcare partners and shareholders.

Epsilon Pharmacy

Epsilon Pharmacy, the Company's newest operating division, has continued to deliver strong commercial and operational progress since its establishment in the first quarter of 2025. In a relatively short period, the business has evolved into a strategically important contributor to Group performance, generating a growing revenue contribution and further strengthening Epsilon's integrated healthcare platform. The division's early success reflects disciplined execution, increasing patient demand and the growing value of an integrated pharmacy offering within the broader healthcare ecosystem.

The Pharmacy division continues to demonstrate the scalability of its operating model by supporting patient access to medicines while maintaining a strong focus on the Quality Use of Medicines (QUM), clinical governance and service excellence. Through the delivery of safe, patient-centred pharmaceutical care, Epsilon Pharmacy is strengthening recurring patient engagement, supporting continuity of care and reinforcing its role as an important growth driver across the Group's integrated healthcare platform.

Consistent with the Company's long-term growth strategy, Epsilon Pharmacy continues to invest in digital capability to enhance the patient experience, improve accessibility and support future operating

leverage. During the second quarter of 2026, the Company successfully launched its dedicated custom-built digital patient portal providing a scalable technology platform integrating patient ordering capabilities, dispensing and ongoing patient management within a single connected ecosystem. The platform is designed to improve workflow efficiency, strengthen patient engagement and retention, and support the continued expansion of the Pharmacy division without a corresponding increase in operating complexity. As patient volumes continue to grow, this investment is expected to enhance operational scalability while supporting capital-efficient growth across the business.

The Company also successfully deployed its physical pharmacy presence with the establishment of its first full-service community pharmacy in Newtown, Sydney. This strategic investment represents an important milestone in Epsilon's pharmacy strategy, extending the Company's integrated healthcare model into a physical community setting while creating additional opportunities to support patients, prescribers and healthcare professionals through a broader range of pharmacy and clinical services. The Newtown pharmacy provides a foundation for future expansion of Epsilon's pharmacy network and strengthens the Company's ability to deliver integrated healthcare solutions across multiple patient touchpoints.

Together, Epsilon's digital and physical pharmacy initiatives create a connected healthcare ecosystem that links clinical consultation, prescribing, dispensing, patient education and ongoing care. This integrated model enhances continuity of care, supports improved patient outcomes, strengthens customer lifetime value whilst also creating operational synergies across the Group's clinics, manufacturing, pharmacy and distribution businesses. The resulting platform provides a scalable foundation from which Epsilon can continue to expand its healthcare offering while responding to evolving patient and healthcare provider needs.

As the division continues to mature, Epsilon Pharmacy is expected to play an increasingly important role in the Group's long-term growth strategy. Supported by ongoing investment in technology, infrastructure and service innovation, the business is well positioned to expand its market presence, diversify recurring revenue streams and enhance operating leverage as it scales. Through disciplined execution and continued investment in capability, Epsilon Pharmacy is expected to make an increasingly meaningful contribution to the sustainable long-term growth of the group.

Capital Management

During the quarter, the Company continued to strengthen its capital structure and funding flexibility in support of its long-term growth strategy.

On 26 June 2026, the Company successfully completed its 'Small Holding Share Sale Facility', generating gross sale proceeds of approximately \$489,753, which were distributed to the 5,157 participating shareholders. This initiative has streamlined the Company's share register reducing the number of shareholders from approximately 7,063 prior to the commencement of the facility, to some 1,688 currently. This initiative reduces share register costs, while improving administrative efficiency. The approximately 24.5 million shares sold under the facility were purchased by the underwriters, which were all current shareholders.

As part of its ongoing capital management program, the Company also terminated its existing \$2.0 million promissory note facility. Amounts previously advanced under the arrangement were transferred to a separate unsecured loan facility, and the Company established a new unsecured debt facility of up to \$1.72 million with a final maturity date of 31 December 2027. These initiatives continue to enhance the Company's funding flexibility and provide an appropriate capital framework to support continued business expansion.

Consistent with its disciplined approach to capital allocation, the Company has strategically increased investment in critical raw materials, active pharmaceutical ingredients (API) and manufacturing consumables to support expanding production volumes and a growing commercial pipeline. This proactive investment strengthens supply chain resilience, enhances production continuity and positions the business to efficiently meet increasing customer demand across both domestic and international markets.

The expanded inventory position provides the operational flexibility required to support larger and more complex manufacturing programs while maintaining the high quality and regulatory standards expected of a GMP-certified contract development manufacturing organisation (CDMO). As manufacturing activity continues to increase, these investments are expected to improve production readiness, reduce supply chain risk and support the efficient scaling of operations.

The Company remains focused on maintaining a disciplined balance sheet and a prudent funding strategy that supports sustainable growth while preserving financial flexibility. This approach provides the capacity to fund organic expansion, support increasing working capital requirements and pursue strategically aligned opportunities, including value-accretive acquisitions, where they enhance long-term shareholder value.

Company & Financial Outlook

The Company enters the next phase of growth with strong operational momentum and a clear strategic focus on disciplined execution, scalable growth and long-term value creation.

Key priorities include:

- **Sustained Revenue Growth:** Building on the record June quarter, the Company is focused on continuing revenue growth through increasing activity across its manufacturing, pharmacy and clinical operations, supported by an increasingly diversified and recurring revenue base
- **Pathway to Sustainable Profitability:** Continued growth in manufacturing volumes, disciplined cost management and increasing operating leverage are expected to support improving financial performance as the Company's integrated healthcare platform continues to scale
- **Expansion of Manufacturing Operations:** The Company continues to strengthen its contract development and manufacturing pipeline, supported by growing domestic demand, expanding international customer engagement and enhanced production capacity following the renewal of its permit
- **Advancing an Integrated Healthcare Platform:** Epsilon remains focused on further strengthening its integrated healthcare ecosystem, connecting sovereign manufacturing, pharmacy, telehealth-enabled clinical services and patient care to improve continuity, operational efficiency and commercial resilience
- **Pharmacy Network Expansion:** The commencement of service at the Company's first community pharmacy in Newtown, Sydney, together with continued investment in digital health capability, including the launch of its patient portal, will continue to enhance patient accessibility, engagement and the scalability of the Pharmacy division
- **Disciplined Capital Management:** A strengthened funding position and prudent balance sheet management provide the flexibility to support continued organic growth, increasing working capital requirements and selective strategic investment opportunities

- **Long-Term Shareholder Value Creation:** The Company remains focused on disciplined execution of its strategic priorities, leveraging its scalable operating platform, diversified revenue streams and integrated healthcare model to support sustainable growth, expanding margins and enduring shareholder value

The Board believes the Company is entering its next phase of growth from a position of increasing operational strength. Supported by a diversified healthcare platform, expanding manufacturing capability, growing recurring revenues and a disciplined approach to capital management, Epsilon is well positioned to capitalise on attractive opportunities across Australian and international healthcare markets. The Company remains focused on executing its strategy, strengthening its competitive position and delivering sustainable long-term value for shareholders.

Outlook Statement – Peter Giannopoulos, Managing Director & CEO

"The June quarter represents an important milestone for Epsilon Healthcare and reflects the continued execution of our long-term growth strategy. Record customer receipts, sustained revenue growth and increasing activity across each of our operating divisions demonstrate the strength of the Epsilon platform and the scalability of our diversified healthcare model.

Epsilon Pharma is entering an important new phase of commercial growth, supported by expanding customer relationships, increasing manufacturing activity and a growing pipeline of opportunities across Australian and international markets. The investments made over recent years in manufacturing capability, regulatory excellence and operational execution are now translating into meaningful commercial outcomes, providing a strong foundation for continued expansion of our contract development and manufacturing operations.

At the same time, Epsilon Clinics and Epsilon Pharmacy continue to strengthen the Group's integrated healthcare ecosystem by enhancing patient engagement, expanding access to high-quality healthcare services and building recurring revenue streams. The commencement of our first community pharmacy in Newtown, together with continued investment in digital health capability, represents an important milestone in advancing our integrated care model, improving patient accessibility and further diversifying the Group's healthcare offering.

The Group's strengthened balance sheet, disciplined capital management and continued investment in capability provide a solid foundation to support the next phase of growth. As we continue to scale our operations, our focus remains on disciplined execution, improving operating leverage, expanding market presence and creating sustainable long-term value for shareholders.

Looking ahead, the Board and management remain focused on executing Epsilon Healthcare's strategic priorities while continuing to strengthen the Epsilon platform. Through ongoing investment in innovation, operational capability and strategic partnerships, the Group has established a strong foundation from which to pursue its next phase of sustainable growth.

We believe Epsilon Healthcare is well positioned to continue expanding its presence across Australian and selected international markets while maintaining a strong commitment to quality, regulatory excellence and positive patient outcomes. The momentum established across the Group provides confidence in our ability to execute our strategy, strengthen our competitive position and deliver value for patients, customers and shareholders."

Summary of recent announcements up to this date

- Company Debt Arrangements – update
- Closure of small holding share sale facility
- Update on proceedings against former director

Other components of cash flow

- Cash on hand at 30 June 2026 was \$1,469,000 compared to \$503,000 in the preceding quarter
- Receipts from customers were \$3,659,000 compared to \$3,140,000 in the preceding quarter
- Cost of goods (COGS) and operating costs were \$1,750,000 compared to \$2,217,000 in the preceding quarter
- Labour payments were \$935,000 in the June 2026 quarter compared to \$712,000 in the preceding quarter
- Administration and corporate costs were \$607,000 compared to \$100,000 in the preceding quarter.
- Related party payments of \$145,000 in the quarter to June 2026 compared to \$145,000 in the preceding quarter and comprised employment related payments to the CEO of \$145,000.

- ENDS -

This ASX announcement has been authorised for release by the Board of Epsilon Healthcare Limited (ASX: EPN).

For further information contact us via corporate@epsilonhealthcare.com.au.



About Epsilon Healthcare

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacture, pharmacy and biotechnology therapeutic products.



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Epsilon Healthcare Limited

ABN

33 614 508 039

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers		3,659	6,799
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		(1,750)	(3,967)
(c) advertising and marketing		(8)	(19)
(d) leased assets		(107)	(191)
(e) staff costs		(935)	(1,647)
(f) administration and corporate costs		(607)	(707)
1.3 Dividends received		-	-
1.4 Interest received		-	-
1.5 Interest and other costs of finance paid		(167)	(182)
1.6 Income taxes paid		-	-
1.7 Government grants and tax incentives		423	423
1.8 Other (provide details if material)		560	560
1.9 Net cash from / (used in) operating activities		1,068	1,069
2. Cash flows from investing activities			
2.1 Payments to acquire or for:			
(a) entities		-	-
(b) businesses		-	-
(c) property, plant and equipment		(713)	(919)
(d) investments		-	-
(e) intellectual property		-	-
(f) other non-current assets		-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(713)	(919)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	200
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	801	1,264
3.6	Repayment of borrowings	(71)	(176)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (lease repayments)	(119)	(211)
3.10	Net cash from / (used in) financing activities	611	1,077

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	503	242
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,068	1,069
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(713)	(919)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	611	1,077

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,469	1,469

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,469	242
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other – monies held in solicitor trust account	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,469	242

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	145
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments</i>		

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	3,820	2,100
7.2	Credit standby arrangements	-	-
7.3	Other	1,595	1,595
7.4	Total financing facilities	5,415	3,695
7.5	Unused financing facilities available at quarter end		1,720
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. The \$2,100,000 secured facility that was provided by investors at 18% p.a. with a maturity date of 30 September 2027. Other financing facilities are; Managing Director, maturity date of 24 March 2027, secured loan at 15% for \$677k, Vehicle finance for a company motor vehicle with Guild Insurance, secured over the financed vehicle, interest rate of 7.08% p.a., maturing 2 March 2030. The Company has a \$1.72m loan facility available from Lekarna Pty Ltd (related party of the Managing Director). Interest accrues on the amount advanced at 15% p.a. with a maturity date of 31 December 2027. The amount drawn as at 30 June 2026 is nil.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	1,068
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,469
8.3	Unused finance facilities available at quarter end (item 7.5)	1,720
8.4	Total available funding (item 8.2 + item 8.3)	3,189
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A	

Quarterly cash flow report for entities subject to Listing Rule 4.7B

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026

Authorised by: By the Board

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.